Novartis' surprise radiotherapy production halt nearing an end as FDA docs shed light on plant woes

One month on, Novartis’ surprise radiotherapy production halt could be nearing its end, the company said Wednesday. Meanwhile, an FDA write-up has shed more light on the manufacturing hitches that likely played a role in the temporary supply squeeze on Novartis’ cancer meds Lutathera and Pluvicto.